Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Revenues:
Grants and contracts	$ 1,613,262	$ 258,237	$ 2,980,734	$ 1,189,634
Operating expenses:
Research and development	5,373,029	6,093,275	10,704,644	12,079,076
General and administrative	3,016,851	3,326,686	6,500,223	5,754,157
Total operating expenses	8,389,880	9,419,961	17,204,867	17,833,233
Loss from operations	(6,776,618)	(9,161,724)	(14,224,133)	(16,643,599)
Other income (expense):
Interest and other income	47,809	70,252	127,765	125,893
Foreign exchange gain (loss)	46,776	641,332	74,910	(51,084)
Change in value of warrant liability	2,795,612	2,543,270	(652,111)	4,263,026
Total other income (expense)	2,890,197	3,254,854	(449,436)	4,337,835
Net loss	(3,886,421)	(5,906,870)	(14,673,569)	(12,305,764)
Net loss attributable to noncontrolling interests	844,310	828,186	1,867,135	1,839,934
Net loss attributable to Cleveland BioLabs, Inc.	$ (3,042,111)	$ (5,078,684)	$ (12,806,434)	$ (10,465,830)
Net loss available to common stockholders per share of common stock, basic and diluted (in Dollars per share)	$ (0.07)	$ (0.14)	$ (0.29)	$ (0.29)
Weighted average number of shares used in calculating net loss per share, basic and diluted (in Shares)	44,948,591	35,745,675	44,887,920	35,701,619